GlassScriptPhysician profile
Sanjay G Patel
NPI 1093959785
$10,186.79
in general payments reported to CMS, 2019-2025
16 companies · $1,718 in 2025
The $1,718 reported for 2025 was more than what 76% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,922 · 2020: $1,947 · 2021: $45.63 · 2023: $145 · 2024: $410 · 2025: $1,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,500 · Food and Beverage: $647 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,500.00 |
| Food and Beverage | $647.40 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,126.18 | 2019-2025 | |
| Photocure INC | $2,049.56 | 2019-2020 | |
| Janssen Biotech, INC. | $365.63 | 2019-2025 | Carvykti, Rybrevant, Erleada |
| Sumitomo Pharma America, INC. | $125.00 | 2024 | Gemtesa |
| Boston Scientific Corporation | $107.12 | 2024-2025 | Ams 700 |
| Pfizer INC. | $78.68 | 2024 | |
| Astellas Pharma US INC | $78.68 | 2019-2025 | Xtandi, Padcev |
| Coloplast Corp | $64.88 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $54.25 | 2024 | |
| Urogen Pharma, INC. | $36.77 | 2023-2024 | Jelmyto |
| Neotract INC. | $29.12 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.81 | 2025 | |
| Merck Sharp & Dohme LLC | $28.29 | 2024 | Keytruda, Lenvima, Welireg |
| Telix Pharmaceuticals | $13.82 | 2023 | Illuccix |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.